Sophiris Bio provides enrollment update on topsalysin Phase 2b study
Sophiris Bio provided an update on clinical trial enrollment of its Phase 2b study of topsalysin as a treatment for men with clinically significant localized prostate cancer. Patient enrollment is near completion, and the remaining patients are being scheduled to receive treatment within the next few weeks. Sophiris expects the study will be fully enrolled by the end of October. The company expects biopsy data from all patients dosed with the first administration of topsalysin to be available late in the first quarter of 2018. "Interest in this study has been strong, and the remaining patients are being scheduled for treatment in the next few weeks," said Randall Woods, president and CEO of Sophiris. "We look forward to completing enrollment, and, assuming enrollment is completed as expected, initial biopsy results will be available toward the end of the first quarter of 2018."